Keymed Biosciences Inc. (HKG:2162)
Hong Kong
· Delayed Price · Currency is HKD 59.10
+0.15 (0.25%)
Dec 5, 2025, 4:09 PM HKT
Keymed Biosciences Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -257.34 | -515.24 | -359.36 | -308.12 | -3,887 | -818.58 | Upgrade
|
| Depreciation & Amortization | 93.44 | 91.84 | 68.78 | 35.79 | 20.94 | 18.97 | Upgrade
|
| Other Amortization | 2.33 | 1.39 | 0.39 | 0.34 | 0.08 | 0.02 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.08 | 1.08 | 0.07 | 0.39 | 0.71 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | - | -0.16 | Upgrade
|
| Loss (Gain) on Equity Investments | 4.12 | 5.26 | 4.75 | 9.71 | 0.72 | - | Upgrade
|
| Stock-Based Compensation | 32.88 | 34.35 | 40.08 | 48.57 | 116.82 | - | Upgrade
|
| Other Operating Activities | -143.99 | -81.49 | -78.62 | -182.94 | 3,531 | 680.58 | Upgrade
|
| Change in Accounts Receivable | -90.55 | -35.76 | -27.09 | 3.98 | -3.98 | - | Upgrade
|
| Change in Inventory | -80.2 | -55.07 | -11.86 | -28.1 | -9.55 | -3.54 | Upgrade
|
| Change in Accounts Payable | 19.2 | -3.48 | 14.58 | 12.13 | -0.63 | -0.06 | Upgrade
|
| Change in Unearned Revenue | -16.41 | -0.45 | -0.81 | - | -7 | 10.3 | Upgrade
|
| Change in Income Taxes | -6.51 | -6.19 | -1.32 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 28.47 | -34.04 | 46.8 | 6.32 | 23.99 | -6.89 | Upgrade
|
| Operating Cash Flow | -604.67 | -789.63 | -303.62 | -401.93 | -214.64 | -119.36 | Upgrade
|
| Capital Expenditures | -250.06 | -207.91 | -378.49 | -278.82 | -171.79 | -19.81 | Upgrade
|
| Sale (Purchase) of Intangibles | -5.06 | -6.58 | -4.12 | -0.73 | -1.07 | -0.09 | Upgrade
|
| Investment in Securities | 0.3 | 162.4 | 700.46 | -575.02 | -1,870 | -104.88 | Upgrade
|
| Other Investing Activities | 162.35 | 119.8 | 150.35 | 208.98 | 6.95 | 11.71 | Upgrade
|
| Investing Cash Flow | -92.13 | 67.71 | 468.2 | -645.59 | -2,036 | -113.07 | Upgrade
|
| Long-Term Debt Issued | - | 468.79 | 360 | 89.95 | - | - | Upgrade
|
| Total Debt Issued | 433.9 | 468.79 | 360 | 89.95 | - | - | Upgrade
|
| Short-Term Debt Repaid | - | - | -0.23 | -0.33 | -41.82 | -5.61 | Upgrade
|
| Long-Term Debt Repaid | - | -135.55 | -93.66 | -14.52 | -12.91 | -5.46 | Upgrade
|
| Total Debt Repaid | -293.71 | -135.55 | -93.88 | -14.85 | -54.73 | -11.08 | Upgrade
|
| Net Debt Issued (Repaid) | 140.19 | 333.24 | 266.12 | 75.1 | -54.73 | -11.08 | Upgrade
|
| Issuance of Common Stock | 791.68 | - | - | - | 2,888 | - | Upgrade
|
| Repurchase of Common Stock | - | -32.43 | -32.9 | -51.14 | - | - | Upgrade
|
| Other Financing Activities | -26.39 | -16.91 | -161.09 | -32.03 | -8.5 | 15 | Upgrade
|
| Financing Cash Flow | 905.48 | 283.9 | 72.13 | -8.06 | 3,638 | 7.4 | Upgrade
|
| Foreign Exchange Rate Adjustments | 23.12 | 5.41 | 10.25 | 139.03 | -66.65 | -8.17 | Upgrade
|
| Net Cash Flow | 231.8 | -432.62 | 246.96 | -916.55 | 1,321 | -233.2 | Upgrade
|
| Free Cash Flow | -854.73 | -997.55 | -682.11 | -680.76 | -386.42 | -139.17 | Upgrade
|
| Free Cash Flow Margin | -98.00% | -233.00% | -192.63% | -680.33% | -350.44% | - | Upgrade
|
| Free Cash Flow Per Share | -3.25 | -3.81 | -2.61 | -2.61 | -2.40 | -2.07 | Upgrade
|
| Cash Interest Paid | 18.14 | 18.15 | 10.49 | 1.85 | - | - | Upgrade
|
| Levered Free Cash Flow | -491.41 | -565.77 | -714.05 | -410.26 | -231.71 | -96.12 | Upgrade
|
| Unlevered Free Cash Flow | -480.75 | -554.23 | -703.27 | -405.01 | -224.75 | -87.18 | Upgrade
|
| Change in Working Capital | -337.82 | -326.82 | 20.29 | -5.67 | 2.83 | -0.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.